Evaxion Biotech

丹麥 · 研究產業

Evaxion Biotech A/S is a clinical-stage biotechnology company based in Horsholm, Denmark, founded in 2008. The company focuses on developing innovative immunotherapies using artificial intelligence and bioinformatics. Evaxion is publicly traded on the NASDAQ stock exchange. The company specializes in AI-driven immunotherapies targeting cancer and infectious diseases. Its product pipeline includes several candidates: EVX-01 is in Phase 2 trials for metastatic melanoma, EVX-02 is a DNA-based vaccine in Phase 1/2a trials for resected melanoma, and EVX-03 targets various cancers. Additionally, EVX-B1 is in pre-clinical stages for preventing infections from *Staphylococcus aureus*, while EVX-B2 and EVX-B3 focus on diseases caused by *Neisseria gonorrhoeae* and other bacterial pathogens, respectively. EVX-V1 is a viral vaccine candidate targeting Cytomegalovirus. Under the leadership of CEO Christian Kanstrup, Evaxion has a dedicated team of about 46 employees and has experienced significant growth since its IPO in February 2021.